Here are five things to know:
1. The company’s IPO included 10.3 million shares of common stock at an offering price of $15 per share, before underwriting discounts.
2. The IPO also includes 1.3 million shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
3. The company initially filed for a $172.5 million IPO, but downsized it to $135 million.
4. J.P. Morgan and Deutsche Bank Securities acted as joint book-running managers for the offering.
5. ConforMIS focuses on developing and marketing customized orthopedics and knee replacement implants.
More articles on devices:
K2M’s 2Q net revenue hits $55.9M-$56.4M, up 19%: 5 things to know
Are medical device companies ready to share risk? 7 key trends
Amedica responds to FDA questions on spinal device: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
